Results 341 to 350 of about 467,565 (384)

Beyond the Scale: The Hidden Burden of Underweight and Cachexia in Adults with Congenital Heart Defects and Heart Failure-Results from the Pathfinder CHD-Registry. [PDF]

J Clin Med
Kaemmerer-Suleiman AS, Freilinger S, Freiberger A, Dewald O, Achenbach S, Bischoff G, Engel A, Ewert P, Harig F, Hörer J, Holdenrieder S, Kaemmerer H, Kaulitz R, Klawonn F, Koch D, Mentzner D, Nagdyman N, Neidenbach R, Schmiedeberg W, Suleiman MN, Ury E, Pittrow RD, Pittrow LB, Pittrow BA, von Scheidt F, Wagener W, Wolfrum N, Huntgeburth M, Mellert F.   +28 more
europepmc   +1 more source

Safety and effectiveness of anticoagulation therapy in older people with atrial fibrillation during exposed and unexposed treatment periods. [PDF]

Heart
Mitchell A, Watson MC, Welsh TJ, McGrogan A.   +3 more
europepmc   +1 more source

Comparison between DOACs and warfarin for left atrial thrombus in atrial fibrillation patients. [PDF]

Int J Cardiol Heart Vasc
Sunaga A, Nakatani D, Okada K, Kida H, Matsuoka Y, Sakamoto D, Kitamura T, Tanaka N, Egami Y, Masuda M, Watanabe T, Minamiguchi H, Oka T, Inoue K, Hikoso S, Sotomi Y, Sakata Y.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

New anticoagulants

Current Opinion in Hematology, 2006
Abstract Traditional anticoagulant drugs, including unfractionated heparin and warfarin, have several limitations. New anticoagulants have been developed that target a single coagulation factor and have predictable dose-response relationships. These include direct thrombin inhibitors and factor Xa inhibitors.
AGNELLI, Giancarlo, BECATTINI, Cecilia
openaire   +6 more sources

Anticoagulation

Clinical Obstetrics and Gynecology, 1998
Outpatient management of women requiring treatment and prophylaxis against thromboembolic conditions during pregnancy and the postpartum period requires a coordinated effort between the patient, her obstetrician and, in certain cases, a hematologic consultant.
H L, Brown, R A, Bobrowski
openaire   +2 more sources

Pharmacology of Anticoagulants

Disease-a-Month, 2012
Antithrombotic drugs are used for the prevention and treatment of thrombosis. Targeting the various components of thrombosis, these agents include (1) antiplatelet agents; (2) anticoagulants; and (3) fibrinolytic agents. This review focuses on anticoagulants.
Loke, Chandravathi, MD, Ali, Syed, MD, Johari, Vandita, MD   +2 more
openaire   +3 more sources

Novel anticoagulants and the future of anticoagulation

Thrombosis Research, 2009
Since its discovery during the first half of the 20th century by biochemists at the University of Wisconsin, warfarin (along with other vitamin K antagonists) has remained the only oral anticoagulant available to patients at risk for thromboembolism. After nearly 6 decades in clinical practice, we have learned much about warfarin. Although it is highly
openaire   +3 more sources

Anticoagulants

2006
Because of the narrow therapeutic index of warfarin and unfractionated heparin (UFH), monitoring their anticoagulant effects is required. On the other hand, lowmolecular- weight heparin (LMWH) and fibrinolytic agents need to be monitored only under certain circumstances.
Richard C. Becker, Frederick A. Spencer
openaire   +1 more source